Plain-English translation of NCT05576818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a synbiotic preparation—a combination of beneficial bacteria (Lactobacillus acidophilus) and prebiotic fibers—can help improve Parkinson's disease symptoms when taken along with your regular dopamine replacement therapy. Researchers want to understand whether this medication is safe and whether it works as an add-on treatment to help manage the condition.
Parkinson's disease affects the nervous system and can cause movement problems and other symptoms that are difficult to manage. Researchers believe that the gut bacteria may play a role in how well Parkinson's symptoms respond to treatment, and this medication might help restore healthy gut bacteria and improve overall outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups for 3 months. One group will continue their standard Parkinson's medication alone, while the other group will take the probiotic supplement (2 sachets daily) in addition to their regular medication. Throughout the study, you'll be monitored to see how well the treatment works and whether you experience any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Egypt
Phase
Large-scale testing
Sponsor
Tanta University
Enrollment target
~66 participants
Started
June 2022
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
45 Years – 65 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mohamed E Ramadan
Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.